Clinical Trials · NCT07627191
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
- Phase
- EARLY_Phase 1
- Recruitment status
- Recruiting
- Sponsor
- University of Arizona
- Enrollment
- 30
- Start date
- Oct 2026
- Locations
- 1 site, United States
- Primary endpoint
- Incidence of Treatment Emergent Adverse Events [Safety] attributed to GLP1-RA and/or its interaction with chemotherapy